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Because Mongolia has much higher liver disease burden than any other regions of the world, it is necessary to 
provide information on real-time situation of chronic liver disease in Mongolia. In this article, we reviewed studies 
performed in Mongolia from 2000 to 2011 on seroprevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) 
among healthy individuals and patients with chronic liver diseases, and on the practice patterns for the management 
of liver cirrhosis and hepatocellular carcinoma (HCC). According to previous reports, the seroprevalence of HBV and 
HCV in general population in Mongolia is very high (11.8% and 15% for HBV and HCV, respectively). Liver cirrhosis is 
also highly prevalent, and mortality from liver cirrhosis remained high for the past decade (about 30 deaths per 100,000 
populations per year). Among patients with cirrhosis, 40% and 39% are positive for HBsAg and anti-HCV, respectively, 
and 20% are positive for both. The seroprevalence is similar for HCC and more than 90% of HCC patients are positive 
for either HBV or HCV. The incidence of HCC in Mongolia is currently among the highest in the world. The mortality 
from HCC is also very high (52.2 deaths per 100,000 persons per year in 2010). Partly due to the lack of established 
surveillance systems, most cases of HCC are diagnosed at an advanced stage. The mortality from liver cirrhosis and 
HCC in Mongolia may be reduced by implementation of antiviral therapy program and control of alcohol consumption.
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INTRODUCTION
Mongolia has the highest incidence of hepatocellular 
carcinoma (HCC) and liver cirrhosis (LC) worldwide 
(Fig. 1). HCC occurs in 61.9 patients per 100,000 popu-
lation each year, and LC occurs in 350 patients per 
100,000, and its high occurrence has been attributed 
to the high prevalence of chronic viral hepatitis [1]. We 
explain the current situation regarding HCC and LC in 
Mongolia.
ETIOLOGY
The hepatitis B (HBV) and C viruses (HCV) are highly 
prevalent in Mongolia. The seroprevalence of HBV is 
11.8% in the unvaccinated population (meta-analysis of 
eight studies) [2], and that of HCV is 15.6% in the appar-
ently healthy population [3]. 
The prevalence of chronic HCV infection in Mongolia 
is strikingly high considering that the global HCV car-
rier prevalence is estimated to be about 3%, ranging 122    The Korean Journal of Internal Medicine Vol. 27, No. 2, June 2012
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from 0.1 to 10% or more [4]. Therefore, Mongolia has 
the highest prevalence (> 15%) of HCV and (> 10%) HBV 
infection, along with Egypt and Tanzania [5,6]. This 
high prevalence is attributed to improper sterilization 
and disinfection of medical and dental equipment that 
might contribute to the spread of hepatitis viruses [3]. 
Interestingly, most HCV infections are caused by geno-
type 1 (98.8%) in patients with chronic hepatitis, and 
genotype 2 infection is very rare (1.2%) [3]. In this re-
gard, improvements in blood safety as well as the devel-
opment and execution of strict disinfection and steril-
ization guidelines for health-related procedures such as 
phlebotomy, injection, and dental and surgical manipu-
lations are required to control the spread of hepatitis 
viruses in Mongolia. Besides chronic hepatitis C, Mon-
golia is confronted with a high prevalence of chronic 
hepatitis B (Table 1). The HBV surface antigen (HBsAg) 
prevalence is 9-10% of healthy individuals in Mongolia 
[7]. With such a high HBV carrier rate in the general 
population, HBV infection and its associated complica-
tions pose serious health problems. To reduce the rate of 
HBV infection via mother-to-baby transmission during 
infancy, the Mongolian government launched a univer-
sal HBV immunization program in 1991. Most HBV in-
fections are caused by genotype D (88.8%). Genotypes A, 
B, and C infection are rare at 0.9, 0.9, and 6.0% respec-
tively [8]. One study demonstrated that 10-50% of HBV 
immunization attempts failed and that HBV vaccine 
failure is not associated with HBV mutants but is often 
associated with an inability to simultaneously adminis-
ter the vaccine and immunoglobulin at birth.
MORBIDITY, MORTALITY, AND SURVIVAL 
OF HCC AND LC
LC is highly prevalent in Mongolia (Table 2). Most 
LC is attributable to HCV, HBV, and hepatitis D virus 
(HDV), and a small portion is due to alcohol (Fig. 2). 
Among patients with cirrhosis, 40% (95% confidence 
interval [CI], 37 to 43) are HBsAg+; 39% (95% CI, 36 
to 42) are antiHCV+, 20% (95% CI, 18 to 23) are dual+, 
and 1% are negative [9]
 (Fig. 3). In the last 10 years, can-
cers have been second among the causes of mortality 
in Mongolia. According to the 2010 national statistics, 
HCC is the most common malignancy, representing 
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Figure 1. Incidence of liver cancer per 100,000 population as of 2009 (Ministry of Health, Mongolia). Blue area indicates areas of high 
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44.2% of all cancers in Mongolia (Fig. 4). An increase 
in the incidence and deaths from HCC has been ob-
served in recent years (Fig. 5). The incidence of HCC 
is six times higher than the global average (Fig. 6). In 
Europe, the USA, and Japan, HCV is the predominant 
cause of development of HCC, whereas HBV infection 
is the main cause of HCC in Korea. Mortality in males 
is mainly due to cancers of the liver and stomach and 
in females it is most commonly due to liver and cervi-
cal cancers. Higher incidences of cancer are observed 
in adults aged 45 to 60 years (Table 3). The 1-year HCC 
survival rate is 21-24%, that at 3 years is 10-11%, and at 
5 years is 6-8% according to an unpublished Natioanal 
Cancer Center report. No data LC survival are available. 
DIAGNOSIS
Diagnosing LC was until recently problematic. Liver 
biopsy is not routine in Mongolia, only 40-60 are per-
formed each year, mainly for diagnosis of HCC. This is 
due primarily to a shortage of interventional radiolo-
gists and liver pathologists. Noninvasive methods, such 
as Fibroscan, were not introduced until 2011, and > 500 
Table 1. Seroprevalence of HCV, HBV, and HDV among patients hepatocellular carcinoma in Mongolia
 
Dondog et al. 
[9]
Kurbanov et al. 
[10]
Oyunsuren et al. 
[11]
Oyunsuren et al. 
[12]
Tsatsralt-Od et al. 
[8]
Jazag et al. 
[13]
HCV only 27 39 38.9 33.5 14.5 33.3
HBV only 50 3 2.8 45.2 0 43.8
HBV + HDV NA 25 25 NA 17.1 NA
HBV + HCV 21 6 5.6 17.3 5.3   22.85
HBV + HCV + HDV NA 19 18.5 NA 63.2 NA
Values are presented as percentage (%).
HCV, hepatitis C virus; HBV, hepatitis B virus; HDV, hepatitis D virus; NA, not available. 
Table 2. Morbidity and mortality from liver cirrhosis in Mongolia from a national study (2006-2010) 
  2006 2007 2008 2009 2010
Morbidity (per 100,000 population) 43.72 327.62 75.66 358.21 350.72
Mortality (per 100,000 population) 33.55   32.85 31.03   28.92   35.07
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Figure 2. Liver cirrhosis-related deaths in Mongolia. Deaths 
due to liver cirrhosis during 2006-2010 are shown. Mortality 
from liver cirrhosis has been persistently high in the last 5 years.
Figure 3. Viral causes of liver cirrhosis. Seroprevalence of hepa-
titis B virus surface antigen (HBsAg) and anti-HCV in patients 
with cirrhosis in Mongolia, 2000-2009. Anti-HCV, antibodies 
against hepatitis C virus; Anti-HCV+, seropositive for anti-HCV 
only; Dual+, seropositive for both HBsAg and anti-HCV; HB-
sAg+, seropositive for HBsAg only.124    The Korean Journal of Internal Medicine Vol. 27, No. 2, June 2012
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patients have undergone this test to-date. Such methods 
will decrease the diagnostic errors associated with other 
nonspecific conventional methods such as ultrasonogra-
phy (US) and increase the detection of LC, because both 
patients and doctors prefer noninvasive methods. Early 
diagnosis of HCC is of extreme importance in Mongolia.
There is a lack of established HCC surveillance sys-
tems in Mongolia. The number of high-quality US ma-
chines is very low, particularly in rural areas, and the 
quality of the US and examiners is unsatisfactory. Most 
family doctors do not classify their patients as high-, 
moderate-, and low-risk, which makes it difficult to re-
fer patients for dynamic computed tomography (CT) due 
to a fear of frequent radiation exposure. Low-quality US 
machines operated by poorly trained technicians diag-
nose HCC lesions that have grown > 3 cm in most cases. 
Moreover, patient education is unsatisfactory. Many 
patients tend to seek medical attention only after the 
development of jaundice or liver failure. 
High-resolution imaging diagnostic modalities, in-
cluding CT and magnetic resonance imaging, are essen-
tial for a proper HCC diagnosis. Unfortunately, only two 
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Figure 4. Increase in the incidence of hepatocellular carcinoma 
(HCC) in comparison with other cancers. Prevalence of HCC 
among different cancers (%) during three periods since 1975.
Figure 5. Incidence of hepatocellular carcinoma (HCC) since 
1967.  The increase in HCC cases over time in Mongolia (per 
100,000 population) is shown.
Figure 6. Age-adjusted incidence of hepatocellular carcinoma (HCC) in the Asia-Pacific region. Mongolia has the world’s highest inci-
dence of liver cancer, which is six times the global average and increasing.Jazag A, et al. Hepatocellular carcinoma in Mongolia    125
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hospitals perform 2-3 phase contrast CTs at this time. 
In our recent as-yet unpublished study, the most-used 
diagnostic imaging modality for the first examination 
was US in all patients. The second-most common imag-
ing modality was contrast-enhanced CT in 58 (44.9%) 
patients followed by contrast-enhanced CT and hepatic 
angiography in 32 (24.8%). The majority of patients 
had advanced HCC, with 63 (48.8%) in stage III and 49 
(38.0%) in stage IV. It is important to note that no pa-
tient had stage I HCC and only 17 (13.2%) patients had 
stage II HCC.
TREATMENT
The treatment modalities available in Mongolia are 
limited. In our study, surgical resection was performed 
in 16% of patients, and trans-arterial chemoemboliza-
tion (TACE) was carried out in 27% of patients with 
multiple or large tumors. Radiofrequency ablation (RFA) 
is considered curative in conjunction with resection, but 
only 2% of patients received RFA as a first-line treat-
ment and 55% received palliative care. Liver resection 
and TACE remain the mainstream treatment options in 
Mongolia (Fig. 7).
Two surgical methods are used for major hepatec-
tomies: the conventional and Glissonian pedicle ap-
proaches (Fig. 8). The Glissonian pedicle approach 
was introduced in the last few years and has already 
produced positive results. While average blood loss was 
358.5 mL in the Glissonian pedicle approach group, it 
was 747.5 mL during conventional liver resection. Pa-
tients who underwent liver resection using a Glissonian 
pedicle approach survived longer than those who re-
ceived the conventional method (Fig. 9).
DISCUSSION
Viral hepatitis B, C, and alcohol consumption remain 
the main causes of chronic liver diseases, such as chron-
ic hepatitis, LC, and HCC, in Mongolia. Insufficient data 
Hepatectomy
TACE
RFA
Palliative care
55%
16%
27%
2%
2004-2007 (75 patients) 2008-2010 (74 patients)
Right hepatectomy
due to tumor in
5, 8 segments
Other major right
hepatectomies
Figure 7. Management of hepatocellular carcinoma (HCC). Ac-
cording to National Cancer Center statistics, only 16% of patients 
with HCC are eligible for hepatoectomy, 29% are eligible for less-
invasive procedures such as transarterial chemoembolization 
(TACE) or radio frequency ablation (RFA), whereas 55% are not 
eligible for any treatment.
Figure 8. Shift in surgical method has resulted in few right hep-
atectomies. With implementation of the Glissonian technique in 
2008 performance of major right liver resections is unnecessary 
in those patients whose cancers are located only in segments 5 
and 8, and it is possible to preserve the anterior segment, which 
represents 33-35% of the liver, instead of removing 63-65%.
Table 3. Incidence and death from hepatocellular carcinoma in Mongolia from a national study (2006-2010) 
  2006 2007 2008 2009 2010
Incidence  (per 100,000 population) 46.66 51.11 57.25 62.23 63.77
Death (per 100,000 population) 47.48 47.44 49.85 52.22 52.22126    The Korean Journal of Internal Medicine Vol. 27, No. 2, June 2012
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limits our knowledge of the exact burden of HDV as a 
cause of LC and liver tumors. Further study is needed 
to assess HDV seroprevalence in patients with LC and 
HCC. There has been no study of the genetic traits of 
Mongolians as a causative factor for HCC. Although the 
need for such research is debatable, genetic factors can-
not be disregarded without careful investigation. The 
high incidence of HCC and end-stage liver disease must 
be addressed at all levels - etiology, diagnosis, treat-
ment, and prevention. Delayed diagnosis contributes 
greatly to the high HCC and LC mortality rate in Mon-
golia. The national program, which  includes high-risk 
patients and frequent follow-up examinations, must be 
implemented by the government as soon as possible. 
HCC and LC surveillance programs must be started 
countrywide immediately. LC previously raised little 
attention in Mongolia, but it certainly deserves more 
attention, because LC mortality is higher than that 
of gastric cancer. There is a need to train more liver 
pathologists and interventional radiologists, because 
there is currently no distinction made between early 
and advanced HCC in Mongolia. Liver fibrosis staging 
is not assessed by pathologists. With the introduction 
of noninvasive methods such as Fibroscan in 2012, 
LC and fibrosis diagnoses substantially improved. 
Advanced immunohistochemical and other staining 
methods have not been implemented. Only 40-60 liver 
biopsies are performed annually due to the shortage 
of interventional radiologists. Those biopsies are per-
formed mostly for differentiation purposes of space oc-
cupying lesions.
Treatment options should be expanded. Approxi-
mately 60 RFA procedures are performed annually. 
The number of RFAs must be increased or the proce-
dures should be performed in conjunction with other 
treatment methods such as TACE. Technical obstacles 
must be removed and the infrastructure available for 
RFA treatment should be improved. 
Surgical resection must be provided as the first-line 
treatment option for patients who satisfy the criteria. 
The Glissonian pedicle approach shows better results 
in terms of mortality after treatment. Chemotherapy 
is one of the least effective treatment options for HCC. 
Sorafenib, though not officially registered in Mongolia, 
has been under clinical trial in five patients with unre-
sectable HCC at NCC, and the results will be disclosed 
in the near future. Concerns of severe side effects and 
high cost as well as low survival benefit remain obsta-
cles to HCC chemotherapy.
Palliative treatment is the only care for patients not 
qualified for surgery, RFA, or TACE, and 55% of HCC 
patients receive palliative care due to delayed diagno-
sis. Such patients often seek help from spiritual healers 
and take traditional herbal remedies. Some patients 
who qualify for surgical treatment prefer alternative 
medicine.
Liver transplantation is an attractive option for cura-
tive treatment but is currently not performed in HCC 
patients. Only five living donor liver transplantations 
(LDLT) have been performed, all for LC. The infra-
structure, legal, and socioeconomic environment for 
LDLT must be improved greatly, so that as many as 
500 additional procedures can be performed annually.
HCC can be greatly reduced with proper treatment 
of alcohol addiction and hepatitis viruses B, C, and D. 
Standard treatment for HCV, including peg-interferon 
plus ribavirin, was registered in Mongolia only 2-3 
years ago. However, the price is exceedingly high for 
those with middle and lower class incomes. We cal-
culated the total cost of HCV diagnosis and treatment 
on per patient and per country bases. An estimated 
516,994 people are infected with HCV and 150 US$/
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person is needed for a full set of diagnostic tests. A to-
tal of 12,267 US$/person is needed for 48-week peg-
interferon treatment including 1 month of hospital stay, 
whereas classic interferon treatment costs 2,953 US$/
person. Currently, with no insurance coverage for viral 
treatment, a total of 6.34 billion US$ is required to treat 
every citizen with pegylated interferon, and 1.52 billion 
US$ is needed to treat using conventional interferon 
therapy. The financial burden of HCV is so great that 41 
life-years are needed for middle-class Mongolian pa-
tients to save enough money to have the latest hepatitis 
treatment. Poverty and insurance policies are the most 
to blame for this dire situation. HCV treatment will cost 
more than the country’s gross domestic product, which 
stands at 4.2 billion US$ as of 2009. As more oral treat-
ment agents become available in the coming years, it 
is likely that HCV treatment costs will increase before 
they decrease. Thus, it is crucial for the World Health 
Organization, pharmaceutical companies, and other 
international organizations to help countries like Mon-
golia fight HCV.
Treatment for HBV has improved recently. Lamivu-
dine was registered 3 years ago, and tenofovir disoproxil 
fumarate is undergoing registration by the Mongolian 
Federal Drug Administration. Adefovir, telbivudine, and 
entecavir are not yet registered. Despite the affordable 
price of lamivudine for most patients, other regimens 
remain too expensive for low-income patients. Although 
there is no cure for HDV, upcoming trials show promise 
for peg-interferon only, peg-interferon in combination 
with tenofovir, or tenofovir alone treatments.
Alcohol consumption remains one of the major causes 
of HCC in Mongolia, and this issue has to be addressed 
by both doctors and the government. Poverty is the ma-
jor cause of excess alcohol consumption, according to 
many studies. The flourishing alcohol business has to 
be controlled by the government and anti-alcohol laws 
must be implemented.
With the elimination of causes and improvements in 
diagnosis and treatment, we believe that a reduction in 
mortality from HCC and LC by at least by 30% is pos-
sible in the near future. 
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